Tag: Geisinger

FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger

CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids […]

National Institutes of Health awards Geisinger over $3.1 million for research of sudden cardiac death

DANVILLE, Pa., March 4, 2019 /PRNewswire/ — The National Institutes of Health has awarded researchers at Geisinger $3.1 million over the next five years to explore innovative approaches for early, genomics-based detection of arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is a degenerative heart disease responsible […]